PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.06 - 0.06
0.06 - 0.24
2.78M / 3.59M (Avg.)
-1.55 | -0.04
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2651911.03%
10Y CAGR of 2651911.03% while CRN.AX is zero. Bruce Berkowitz would see if incremental growth can widen into a significant edge.
No Data
No Data available this quarter, please select a different quarter.
18.52%
Positive 3Y CAGR while CRN.AX is negative. John Neff might view this as a sharp short-term edge or successful pivot strategy.
195.55%
OCF/share CAGR of 195.55% while CRN.AX is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
307.27%
OCF/share CAGR of 307.27% while CRN.AX is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
-2.96%
Negative 3Y OCF/share CAGR while CRN.AX stands at 27.04%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
156.11%
10Y net income/share CAGR of 156.11% while CRN.AX is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
161.32%
Net income/share CAGR of 161.32% while CRN.AX is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
742.17%
3Y net income/share CAGR above 1.5x CRN.AX's 45.53%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
No Data
No Data available this quarter, please select a different quarter.
69.11%
Equity/share CAGR of 69.11% while CRN.AX is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
-146.29%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.